Capricor Therapeutics, Inc.

NasdaqGS:CAPR Rapport sur les actions

Capitalisation boursière : US$1.9b

Capricor Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Capricor Therapeutics est Linda Marbán, nommé en Jan2010, a un mandat de 16.33 ans. La rémunération annuelle totale est $ 3.52M, composée du salaire de 8.5% et des bonus 91.5%, y compris les actions et options de la société. détient directement 0.37% des actions de la société, d'une valeur de $ 7.12M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 10.4 ans.

Informations clés

Linda Marbán

Directeur général

US$3.5m

Rémunération totale

Pourcentage du salaire du PDG8.52%
Durée du mandat du directeur général16.3yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction4.8yrs
Durée moyenne du mandat des membres du conseil d'administration10.4yrs

Mises à jour récentes de la gestion

Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

Recent updates

CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup

Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.

CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis

Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.

CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case

Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.

CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook

Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.

Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel

Mar 13

CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path

Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.

CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing

Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.

CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path

Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.

CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path

The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.

CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing

Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.

CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative

Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.

CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes

Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

May 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
User avatar

FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel

FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.

New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Mar 29
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Mar 19
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Dec 12
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Dec 06

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Analyse de la rémunération des PDG

Comment la rémunération de Linda Marbán a-t-elle évolué par rapport aux bénéfices de Capricor Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2025US$4mUS$300k

-US$105m

Sep 30 2025n/an/a

-US$82m

Jun 30 2025n/an/a

-US$70m

Mar 31 2025n/an/a

-US$55m

Dec 31 2024US$2mUS$229k

-US$40m

Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$774kUS$221k

-US$22m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$210k

-US$29m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$2mUS$200k

-US$20m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$150k

-US$14m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$229kUS$157k

-US$8m

Rémunération vs marché: La rémunération totale de Linda ($USD 3.52M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.48M ).

Rémunération et revenus: La rémunération de Linda a augmenté alors que l'entreprise n'est pas rentable.

PDG

Linda Marbán (62 yo)

16.3yrs
Titularisation
US$3,521,565
Compensation

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Frank Litvack
Executive Chairman of the Board14.3yrsUS$735.35k0.30%
$ 5.9m
Linda Marbán
Co-Founder16.3yrsUS$3.52m0.37%
$ 7.1m
Anthony Bergmann
CFO & Corporate Treasurer8.3yrsUS$1.67m0.014%
$ 276.2k
Karen Krasney
Executive VP14.2yrsUS$1.27m0.053%
$ 1.0m
Kristi A. Elliott
Chief Operating & Science Officer1yrpas de donnéespas de données
Minghao Sun
Senior Vice President of Quality Control1.3yrspas de donnéespas de données
Mark Awadalla
Chief Development Officer1.3yrspas de donnéespas de données
Micheal Binks
Chief Medical Officer1yrpas de donnéespas de données
Nathaniel Hogan
Director of Biostatistics of Capricor Therapeuticsno datapas de donnéespas de données
Catherine Kelleher
Consultantno datapas de donnéespas de données
4.8yrs
Durée moyenne de l'emploi
65.5yo
Âge moyen

Gestion expérimentée: L'équipe de direction de CAPR est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Frank Litvack
Executive Chairman of the Board14.3yrsUS$735.35k0.30%
$ 5.9m
Linda Marbán
Co-Founder12.5yrsUS$3.52m0.37%
$ 7.1m
George Dunbar
Independent Director12.5yrsUS$325.60k0.025%
$ 480.3k
David Musket
Independent Director12.5yrsUS$380.60k0.15%
$ 3.0m
Karimah Es Sabar
Independent Director4.8yrsUS$299.97k0%
$ 0
Paul Auwaerter
Independent Director2.8yrsUS$284.34k0.0086%
$ 167.8k
Pat Furlong
Member of Scientific Advisory Boardno datapas de donnéespas de données
Eugenio Mercuri
Member of Scientific Advisory Boardno datapas de donnéespas de données
Craig McDonald
Member of Scientific Advisory Boardno datapas de donnéespas de données
Kan Hor
Member of Scientific Advisory Boardless than a yearpas de donnéespas de données
Michelle Eagle
Member of Scientific Advisory Boardno datapas de donnéespas de données
Michael Taylor
Member of Scientific Advisory Board8.3yrspas de donnéespas de données
10.4yrs
Durée moyenne de l'emploi
67yo
Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la CAPR est chevronné et expérimenté ( 10.4 années d'ancienneté moyenne).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/01 00:41
Cours de l'action en fin de journée2026/05/01 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Capricor Therapeutics, Inc. est couverte par 10 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Matthew VeneziaAlliance Global Partners
Madison Wynne El-SaadiB. Riley Securities, Inc.
Kristen KluskaCantor Fitzgerald & Co.